---
title: "博拓生物在2026年第三季度業績説明會上表示，公司堅持創新驅動，以POCT快速診斷為主業。 — 博拓生物 — DecisionGateway"
description: "statement by 博拓生物, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1e741-81e0-737f-bb60-09b2d9caf2d0"
meta:
  "og:description": "statement by 博拓生物, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "博拓生物在2026年第三季度業績説明會上表示，公司堅持創新驅動，以POCT快速診斷為主業。 — 博拓生物 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **博拓生物在2026年第三季度業績説明會上表示，公司堅持創新驅動，以POCT快速診斷為主業。**

A statement by [**博拓生物**](https://dgw.tmarket.io/actors/01a1e741-81bb-79c9-ba9f-0d8978edf093). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *博拓生物在2026年第三季度業績説明會上表示，公司堅持創新驅動，以POCT快速診斷為主業*

stockintelligencenewsPublished 2026-11-11 [ Read source](https://t.me/stockintelligencenews/5715708)

[**博拓生物 dossier **](https://dgw.tmarket.io/actors/01a1e741-81bb-79c9-ba9f-0d8978edf093)

## **Discussion**

## **Related claims**

[**The statements were made at the company's Q3 2026 results briefing.**鐵龍物流 · statement](https://dgw.tmarket.io/claims/01a1e74f-8c1a-7e24-803a-26282eff06c4) [**公司提升POCT產品綜合競爭力。**博拓生物 · commitment](https://dgw.tmarket.io/claims/01a1e741-821d-7269-99f5-5b89859bd1d6) [**TAT Technologies published record results for the third quarter and the nine months of 2026, with growth in revenues, profit margins and EBITDA.**תאת טכנולוגיות · statement](https://dgw.tmarket.io/claims/01a1de08-56bc-7de3-bd38-586501d1d6b4) [**At the investor day, management highlighted AI-driven drug discovery (AIDD) as an emerging structural growth driver.**管理層 · statement](https://dgw.tmarket.io/claims/01a1e738-e12c-74a2-b2e5-da8e5c3b849b) [**The embodied intelligence industry platform established by 晉拓股份, 南大開發 and 宇樹科技 has officially launched.**post author · statement](https://dgw.tmarket.io/claims/01a1e72f-40c4-7e50-90c9-bbc09212d565) [**This is the first case clinically demonstrating the strategic advantage IMVT-1402 has over Batoclimab.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-39ae-7ac2-bbb4-dc8ff1688a98)

## **More claims by 博拓生物**

[**公司開闢長期潛在增長曲線。**prediction](https://dgw.tmarket.io/claims/01a1e741-825a-7767-a229-fbba6c31c39b) [**公司通過設立產業投資平台參股投資或併購、參與產業基金等方式探索腦機接口、AI醫療等新興方向。**commitment](https://dgw.tmarket.io/claims/01a1e741-8243-7c48-a9bf-fda0746b3d2f) [**公司在醫療前沿領域積極佈局。**statement](https://dgw.tmarket.io/claims/01a1e741-8230-730f-815e-74d3c094f8d2) [**公司提升POCT產品綜合競爭力。**commitment](https://dgw.tmarket.io/claims/01a1e741-821d-7269-99f5-5b89859bd1d6) [**公司推進微流控熒光檢測平台高端、高質量的微流控芯片檢測試劑開發。**commitment](https://dgw.tmarket.io/claims/01a1e741-8209-78f6-bdd5-9f96e4398be7)

[All claims by 博拓生物](https://dgw.tmarket.io/claims?claimant_id=01a1e741-81bb-79c9-ba9f-0d8978edf093)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,500+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1e741-81e0-737f-bb60-09b2d9caf2d0#webpage","@type":"WebPage","description":"statement by 博拓生物, recorded recently — verbatim quote and source citation.","name":"博拓生物在2026年第三季度業績説明會上表示，公司堅持創新驅動，以POCT快速診斷為主業。 — 博拓生物 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1e741-81e0-737f-bb60-09b2d9caf2d0","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1e741-81e0-737f-bb60-09b2d9caf2d0#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1e741-81e0-737f-bb60-09b2d9caf2d0"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1e741-81e0-737f-bb60-09b2d9caf2d0#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"博拓生物在2026年第三季度業績説明會上表示，公司堅持創新驅動，以POCT快速診斷為主業。","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1e741-81e0-737f-bb60-09b2d9caf2d0#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-11","isBasedOn":"https://t.me/stockintelligencenews/5715708","text":"博拓生物在2026年第三季度業績説明會上表示，公司堅持創新驅動，以POCT快速診斷為主業","url":"/claims/01a1e741-81e0-737f-bb60-09b2d9caf2d0","spokenByCharacter":{"@type":"Person","name":"博拓生物","@id":"/actors/01a1e741-81bb-79c9-ba9f-0d8978edf093"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
